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Abstract
Non-melanoma skin cancer (NMSC) is the most common type of cancer among white 
skin individuals worldwide with an increasing incidence over the last years. NMSC is 
mostly treated with surgical or non-invasive methods such as cryotherapy or topical che-
motherapeutics. Over the last years, there has been a rapidly growing interest in the use 
of photodynamic therapy (PDT) which is a well-tolerated, safe and effective alternative 
treatment option. PDT involves a photosensitizer, a light source and tissue oxygen and 
is based on a photo-oxidation reaction in the target tissue which results to a selective 
destruction of the cancer cells. PDT has been approved for treatment of actinic keratosis, 
Bowen’s disease and basal cell carcinoma in Europe. Off-label uses include treatment 
of invasive squamous cell carcinoma, cutaneous T-cell lymphoma, Kaposi’s sarcoma, 
Paget’s disease and prevention of recurrence of squamous cell carcinoma in organ-trans-
plant recipients. Also combination of PDT with other treatment options such as cryother-
apy, surgery and topical therapies has been reported with improved efficacy, tolerability 
and long-term results. Development of novel photosensitizers and light sources together 
with targeted delivery systems will increase specificity, efficiency and treatment field 
of PDT in the future. This chapter aims to give the reader an overview of the important 
applications of PDT, including indications, approved treatments, advantages and disad-
vantages of this method such as future trends.
Keywords: photodynamic therapy, photosensitizer, non-melanoma skin cancer, basal 
cell carcinoma, squamous cell carcinoma, actinic keratosis
1. Introduction
Non-melanoma skin cancer (NMSC) is the most common type of cancer among white-skin 
individuals worldwide with an increasing incidence over the last years. Clinical examination, 
evaluation through dermoscopy and histopathology are the gold standard methods for the 
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diagnosis of skin cancer. These diagnostic procedures together with the location and extent of 
the tumor will determine the choice of treatment. NMSC is mostly treated with surgical exci-
sion or non-invasive methods such as cryotherapy, application of topical chemotherapeutics 
or radiotherapy. However, limitations and side-effects of the conventional therapies motivate 
the development of other techniques.
Over the last years, there has been a rapidly growing interest in the use of photodynamic therapy 
(PDT) for treatment and prevention of skin cancer. PDT is a well-tolerated, safe and effective 
alternative in the treatment and prevention of non-melanoma skin cancer. Nowadays, it is mostly 
used for the treatment for actinic keratosis but also for in situ squamous cell carcinoma (Bowen’s 
disease), superficial- and also nodular basal cell carcinoma with acceptable response rates [1].
As a non-invasive targeted therapy with a low spectrum of adverse effects, PDT has advan-
tages concerning the patient comfort and achieves excellent cosmetic results while the 
response rates are comparable to that of other surgical and nonsurgical procedures [2].
The aim of this chapter is to provide an assessment of the current state of use of PDT in the 
treatment of skin cancer and focus on new developments and future aspects of this procedure 
in the treatment of non-melanoma skin cancer.
2. General principles of photodynamic therapy
The main principle of photodynamic therapy is based on photooxidation occurring in a target 
tissue. Key components of this technique are a photosensitizer, oxygen and light within the 
absorption spectrum of the photosensitizer.
The mechanism of action of photosensitizers is divided in two different types. Type I reac-
tion involves direct oxidation by hydrogen peroxide, superoxide anion radical and hydroxyl 
radical of biological targets (DNA, membranes and proteins), while type II reaction includes 
oxidation mediated by singlet oxygen through energy transfer from triplet states to molecu-
lar oxygen [3]. The production of reactive oxygen species (ROS) depends on the uptake of a 
photosensitizing drug by the tumor, the subsequent irradiation of the tumor with visible light 
of an appropriate wavelength and the presence of an adequate concentration of molecular 
oxygen [3]. A photosensitizer can induce tissue damage either directly through induction 
of necrosis or apoptosis or indirectly by affecting its vascularization. It is important to know 
that in absence of any one of these components, the effectiveness of photodynamic response 
is disturbed. Therefore, careful selection of photosensitizer, type of tissue photosensitization 
and light dosimetry is essential [4, 5].
2.1. Photosensitizers
Photosensitizers (PSs) are substances capable of making an organism, a cell or a tissue photo-
sensitive by inducing the photo-oxidation of several types of molecules through energy transfer 
processes. The development of an ideal photosensitizer remains a major challenge since several 
characteristics have to be taken into consideration. It is important for the photosensitizer to be 
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chemically pure, to have chemical and physical stability, high selectivity and to be activated 
only in the presence of light, with no dark toxicity. The wavelength of the light used in PDT 
has to be longer than those in the UV spectrum in order to minimize the risk of UV-induced 
skin cancer. Its absorption peak should be a wavelength > 630 nm, where it presents an optimal 
tissue penetration. Furthermore, it should have a high absorption capacity being able to be 
rapidly and predominantly retained in the tumor tissue and eliminated from the organism in 
order to prevent the risk of prolonged systemic photosensitivity. The photosensitizer should 
also have a clearance from the tumor tissue which is slower than that of normal cells and be 
capable to generate reactive oxygen species [6].
For dermatological appliance, only haematoporphyrin derivatives like porfimer sodium 
(Photofrin H) or protoporphyrin IX (PPIX)-inducing precursors like 5-aminolevulinic acid 
(ALA) or methyl aminolevulinate (MAL) are of practical concern. Therefore topical photosen-
sitizers are preferred for use in dermatology. After topical application, both ALA and MAL 
are mainly taken up by cells of epithelial origin and are converted into photosensitizing por-
phyrins [7]. After an incubation period, followed by illumination with visible light to activate 
the photosensitizer a type II photo-oxidation reaction takes place and produces reactive oxy-
gen species (ROS), which destroy cell membranes and structures, ultimately leading to cell 
death. The appropriate wavelength of light, concentration of sensitizer and molecular oxygen 
level in the tissue are all critical for the efficacy of PDT [8].
2.2. Topical photosensitizing drugs
Current clinical practice utilizes the use of topical photosensitizers in PDT such as 5-aminolevulinic 
acid (5-ALA) or methyl-aminolevulinate (MAL), which are both precursors in the biosynthe-
sis of protoporphyrin IX (PpIX) (Figure 1). PpIX is a native photosensitizing compound that 
accumulates in the cells and has an absorption peak at 505, 540, 580 and 630 nm.
The 5-ALA-based photosensitizers are not photoactive themselves, but show a preferential 
intracellular accumulation in the tissue target and particularly in the tumor cells where they 
are metabolized by the haem biosynthesis into photosensitizing porphyrins [7, 9].
Although these two molecules share a similar mechanism of action as prodrugs that lead to 
production of photoactive PpIX, they have notable differences.
ALA is a hydrophilic molecule and is used to treat more superficial lesions due to its modest 
tissue penetration [10]. Although the uptake of ALA is non-selective, accumulation of PpIX in 
tumor cells may occur selectively through alterations in enzymatic activity in the heme syn-
thesis pathway. It is supposed, that activity of porphobilinogen deaminase (PBGD) increases 
in tumor tissue. PBGD synthesizes a precursor of PpIX and thus increases production of 
PpIX. The accumulation of PpIX in tumor tissue is further enhanced by decreased activity of 
ferrochelatase, which converts PpIX to heme [11]. Another postulated mechanism of selectiv-
ity for topical ALA relates to the altered stratum corneum of tumoral skin.
MAL is a more hydrophobic molecule which can better penetrate through the cell membranes 
and more easily reaches the deepest epidermal layers. Therefore, shows MAL a higher selec-
tivity for tumor cells compared with ALA. However, the biosynthesis of protoporphyrin IX 
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production from MAL is slightly slower because of the need of hydrolysis of this compound. 
Adjacent unaffected structures such as epidermis and mesenchymal cells show a much less 
pronounced production of porphyrin, thus leading to a high ratio between tumor and sur-
rounding tissue [12]. This technique enables a selective detection (fluorescence detection) and 
selective destruction of the target tissue with minimal harm to the surrounding one (Figure 2).
Interestingly, there seems to be no significant differences in the efficacy between ALA- and 
MAL-PDT in the treatment of NMSC, as recently shown [13].
Standardized protocols for the application of both photosensitizing drugs have been devel-
oped. For MAL-PDT, there is a standardized protocol of two treatments 1 week apart for basal 
cell carcinoma (BCC) and Bowen’s disease (BD), but with only one initial treatment for actinic 
keratosis (AK), repeated at 3 months, only if required [1]. MAL is typically applied for 3 h, 
but Levulan ALA although licensed for an 18–24 h application, is widely used with shorter 
application intervals around 1 h [14]. A shorter incubation for MAL-PDT for 1 h in AK can 
also be performed since no significant difference in clearance rates have been reported [15].
Figure 2. Selective detection of fluorescence due to prior application of ALA on a superficial BBC lesion.
Figure 1. Molecular structures of 5-aminolevulinic acid (5-ALA) and methyl-aminolevulinate (MAL).
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Several novel topical photosensitizers such near-infrared (NIR) bacteriochlorin analogues [16], 
silicon phthalocyanine, alone [17] or in combination with C6-pyridinium ceramide (LCL29) 
[18] have promising characteristics for use in PDT but they are still in experimental level.
2.3. Light sources and action mechanism
Distinct light sources can be used for PDT. For therapy, the tissue must be irradiated with 
light at appropriate wavelengths (within the absorption spectrum of porphyrins) and the 
light source should have special characteristics for use in PDT in NMSC. Light should be 
perfectly absorbed by the photosensitizer, achieve a desirable penetration depth and thus 
reaching the target tissue, have an adequate power and duration in order to trigger the PDT 
reaction and cause minimal discomfort or side-effects such as erythema, crusting or dyspig-
mentation [19].
Porphyrins exhibit a very typical absorption spectrum with the highest peak at approximately 
405 nm, called the Soret-band. Several so-called Q-bands also exist, the last having an absorp-
tion peak at 635 nm. Although the peak is much smaller than that at 405 nm, this wavelength 
is preferentially used for illumination since light at red spectrum results in a higher tissue 
penetration [20, 21].
The light sources available for PDT belong to three major groups: broad spectrum lamps, 
diode lamps and lasers. For a successful PDT-treatment using ALA- or MAL-PDT both laser 
and incoherent light sources can be used and there is no difference regarding the profile of 
light. Even pulsed laser light sources matching one of the Q-bands at 585 nm have comparable 
results to an incoherent light source in the treatment of AK [22]. Also the use of a long-pulsed 
dye laser at 595 nm seems to be effective for the same indication [19]. The incoherent light 
sources include the halogen lamps, the light-emitting diode (LED) lamps and intense pulsed 
light (IPL) lamps. Due to the possibility of distinct emission geometries and lower costs are an 
attractive option [23, 24].
Light with wavelengths of 635 nm is capable of penetrating the skin to a depth of approxi-
mately 6 mm compared to 1–2 mm with a wavelength of 400–500 nm. The effective therapeu-
tic depth, however, appears to be close to 1–3 mm when 635 nm is used. This is due to the 
capacity to produce a photodynamic reaction, which depends on the dose of light and also on 
the quantity of photosensitizer used in the target tissue [25].
Advantages of lasers are that they provide a specific wavelength that corresponds to the peak 
absorption of the photosensitizer. Since lasers can emit high flux monochromatic light and have 
a focal precision, enable the treatment of small lesions with minimal damage to the surrounding 
tissue and within a short time interval. Nevertheless, for the treatment of dermatological condi-
tions using PDT, lasers show no advantage compared to over cheaper and more practical options 
with non-coherent light sources. These sources emit a large radiation field, enabling larger areas 
of the skin surface to be treated [26]. However, the costs for purchasing and maintenance of these 
laser systems are extremely high. The gold standards in topical PDT are light sources with wide 
illumination fields which accomplish the simultaneous illumination of larger areas.
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Here incoherent light sources are preferred, either lamps or light-emitting diodes (LEDs) 
which match the absorption maxima of the ALA- or MAL-induced porphyrins [25, 27, 28]. 
Using broad-spectrum red light (580–700 nm), a light dose of 100–150 J/cm2 (100–200 mW/
cm2) is essential for tissue damage. The light intensity should not exceed 200 mW/cm2 in 
order to avoid hyperthermic side effects [27]. After a photosensitizer has been activated 
with light of appropriate wavelength, it comes to the generation of reactive oxygen spe-
cies (ROS), in particular singlet oxygen. Depending on the extend and localization of the 
target tissue, these ROS modify either cellular functions or induce cell death by necrosis or 
apoptosis [29].
MAL-PDT using daylight has been shown to be as effective as conventional red light MAL-
PDT in the treatment of AK, but with minimal to no therapy-related pain [30].
There is also an option for ambulatory PDT, where portable LED light source with low irradi-
ance can be applied for over 100 min. Satisfactory results with clearing 11 of 17 lesions and 
minimal pain have been reported for treatment of BD and superficial BCC [31].
2.4. Cutaneous fluorescence diagnosis
Topical photosensitizing drugs can also be applied for diagnostic purposes. Cutaneous 
fluorescence diagnosis (FD) is a promising dermatological procedure based on the combi-
nation of a local application of a photosensitizer such ALA or MAL and the use of a light 
source adapted to the absorption spectrum of these molecules. After topical application 
of ALA or MAL on the skin lesional and non-lesional areas, they are irradiated with blue 
light (408 nm). As PpIX shows red fluorescence when excited by blue light, PpIX accumu-
lating cells can be visualized [32]. The detection of skin surface fluorescence can be made 
either by using simple handheld Wood’s lamp (long wave UVA) or by using CCD camera 
systems coupled to digital imaging and helps the clinician to differentiate lesions and 
perform either a guided biopsy or a controlled and complete resection of tumor, or even 
to identify persistent or recurrent disease. By using a commercial digital CCD camera 
system, together with digital imaging, the contrast of the acquired fluorescence images 
can be significantly enhanced and allows the determination of a threshold, which can be 
utilized either for a directed biopsy or for preoperative planning when Moh’s surgery is 
scheduled [33].
Furthermore, FD is probably a helpful tool to prove the efficacy of PDT. Limitations of this 
technique are the difficult interpretation and the low reproducibility of the obtained data. 
Most studies have mainly focused on BCC [34], AK and SCC [35] so far. Truchuelo et al. [36] 
showed that FS is a valid diagnostic tool in the diagnosis and follow up of BD with a com-
parable evaluation to clinical and histopathological results, a specificity of 85.7% and a 100% 
sensitivity (higher than clinical evaluation alone).
Although, FS cannot be used to differentiate the different stages of AK, it was shown that 
through differences in fluorescence ratio between AK and SCC, these entities can be differen-
tiated [35, 37].
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2.5. Practical application, tolerability and side effects
PDT with ALA or MAL conventionally begins with the topical application of the photosen-
sitizers on the target area. In case of hyperkeratotic lesions, a keratolysis using an ointment, 
wet cloth or by slight non-bleeding curettage has to be performed prior to the application of 
photosensitizer as this may be the cause of a poor therapeutic response [38, 39].
ALA has been applied in various formulations such as creams or gels, sometimes with pen-
etration enhancers. ALA preparations are usually applied to the target lesions with little over-
lap to the surrounding tissue for 4–6 h prior to illumination under occlusion and with a light 
protective dressing or clothing [40].
MAL is mainly applied in ointments which have a shorter incubation time of 3 h due to the 
preferential uptake and their higher selectivity [41, 42]. The entire area is then covered with 
an occlusive foil to allow a better penetration during the incubation which is then followed by 
illumination with blue light.
Pain is a major and serious adverse event during PDT and can lead to discomfort of the patient 
to incomplete treatments and need for repeat treatments [43]. The pain or a kind of burning 
sensation is mostly experienced during the time of illumination and a couple of hours later [9].
In a previous study it could be shown that MAL-PDT induces less pain in comparison to 
ALA-PDT which can be partially explained due to the differences in selectivity between the 
two substances [44].
Various pain-relieving approaches have been used in order to reduce pain during PDT. During 
extensive treatment fields administration of oral analgesia can be useful [45]. The application 
of local anaesthetics like lidocaine/prilocaine substances prior to illumination is generally not 
recommended. As previously shown also application of morphine 0.3% gel 15 min prior to 
illumination did not result in a significant reduction of pain as compared to a placebo gel [46]. 
Furthermore, due to their high pH local anaesthetics carry the risk of interaction during the 
incubation period of ALA/MAL and thus inactivate the photosensitizing drug. Wiegell et al. 
showed that application of cold water and regular pauses in illumination led to a consider-
able reduction of pain during PDT [47]. An alternative option with satisfactory results is a 
concurrent cold air analgesia which has been shown to improve the tolerability of ALA- and 
MAL-PDT [48]. Also analgesia by means of a nitrous oxide/oxygen mixture during PDT led to 
an overall reduction in pain of 55.2% and willingness of patients to continue the therapy [43].
Previous studies have also demonstrated that the type of light applied plays also a role in the 
development of pain. Therefore, PDT with the use of PDL coherent light, when compared to 
LED incoherent light led to less pain and increased willingness of patients to further perform 
the therapy [49].
Besides pain also burning and prickling sensations are common side effects of PDT. These 
sensations are usually mild to moderate in intensity and reversible [50]. In a previous 
study with ALA-PDT used to treat AK, it was found that about 96% of patients experienced 
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stinging/burning sensations at 6 and 11 min during illumination. However, only 10% of 
them characterized pain intensity as severe [51].
Localized erythema and oedema in the treated area can also occur. Rarely a dry necrosis 
sharply restricted to the tumor areas can manifest over the next few days which is followed 
by complete re-epithelialization. Also pigmentary disorders presented as hypo- or hyper-
pigmentation are also potential adverse effects of PDT treatment but are rare and of tempo-
rary duration. More often, pigmentary disorders have been noted prior to PDT-treatment and 
resolved at the last follow-up evaluation [51]. Allergic contact dermatitis, although extremely 
rare, can also occur by presence of sensitization against active ingredients of the applied sen-
sitizers [52].
Due to the high selectivity and photosensitization preferentially to cells of epithelial origin and 
no fibroblasts or dermal fibers, usually no scarring or ulceration is observed clinically [9, 40]. 
Also irreversible alopecia could not be observed after PDT treatment series on the scalp despite 
the concomitant sensitization of pilosebaceous units [40, 53]. With the exception of a porphyria 
or previous allergic reactions to the active ingredients of the applied sensitizers in the medical 
history, there are no severe limitations to performance of ALA- or MAL-PDT. PDT treatment 
can be repeated and applied even in areas with prior exposure to ionizing irradiation [54]. 
During PDT treatment, both patient and clinic staff should be wearing protective goggles to 
avoid the risk of eye damage [38].
3. Photodynamic therapy in non-melanoma skin cancer
PDT is nowadays widely applied in the therapy of NMSC. The range of possible indications 
is expanding continuously, including non-malignant conditions and even premature skin 
aging due to chronical sun exposure. MAL is approved for use in Europe and United States 
in combination with red light for treating AK, superficial or nodular BCC and in-situ SCC or 
BD. A combination of an alcohol-containing ALA solution in a special applicator (Levulan 
Kerastick) and blue light is also approved in United States for the treatment of AK. For ther-
apy of multiple lesions or by immunodeficient patients, PDT may be the treatment of first 
choice [23]. PDT is also indicated for patients with important comorbidities when surgery and 
radiotherapy are contraindicated. It may also be used for palliative care in combination with 
chemo- or radiotherapy for advanced tumors with skin metastases.
In the dermatological daily practice, PDT has some advantages compared to conventional treat-
ments such as radiotherapy, chemotherapy and surgery. Some of them are the limited dura-
tion of the treatment, the efficiency and the good cosmetic outcome due to its high selectivity.
3.1. Actinic keratosis
Actinic keratoses (AKs) are premalignant disorders of keratinocytes occurring on chronically 
sun-damaged skin. Although a spontaneous regression may occur in up to 20% of cases [55] 
there is a risk of transformation to SCC within one year between 0.025 and 16% [56]. Since AK 
manifests in chronically sun-damaged skin and there are often multiple lesions the exact risk 
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of malignant transformation for individual lesions cannot be estimated [57]. Various treat-
ment options such as cryotherapy, topical immunomodulation, laser and PDT are highly 
effective and recommended not only for individual lesions but also for field treatment [1, 58]. 
Several studies have been performed analyzing the efficacy of both ALA-PDT and MAL-PDT 
and comparing them with other procedures in treatment of AKs. Thin AK lesions or lesions 
of moderate thickness on the face and scalp respond well to topical PDT with clearance rates 
89–92% 3 months after therapy [59]. A phase III clinical trial of ALA-PDT for the treatment of 
multiple AKs of the face and scalp found that 89% of patients had a remission of 75% or more 
of their AKs after 3 months of treatment [60]. Tschen et al. [51] reported remission rates of 78% 
12 months after a single ALA-PDT treatment, with few adverse effects.
European guidelines recommend that for AK, MAL-PDT should be performed as a single 
treatment and repeated if required after 3 months, reflecting equivalent efficacy in a compa-
rable study with a double therapy 1 week apart [59].
Also compared with other treatment options such as cryotherapy PDT achieves favorable out-
comes [61, 62]. A novel self-adhesive patch ALA-PDT war superior to cryotherapy and placebo 
after 12 weeks in a multicenter phase III trial [61]. Also MAL-PDT achieved better therapeutic 
results compared to single cycle cryotherapy and placebo after 3 months in another large pro-
spective randomized study [62]. When compared to double cycle cryotherapy for AKs on the 
extremities in a large randomized multicenter study MAL-PDT showed superior efficacy [63].
When compared with the topical application of 5-fluouracil (5-FU) twice daily ALA-PDT 
showed similar outcomes in mean lesion reduction [64]. Recently Tanghetti et al. reported that 
patients with AK who had been treated with 5-FU prior to ALA-PDT showed a significant 
decrease of clinical lesions after 1 and 3 months compared to these substances alone, which 
indicates that 5-FU has a synergistic role to ALA-PDT [65].
No significant difference was found in treatment responses of facial AKs to topical 5% imiqui-
mod compared to ALA-PDT in a randomized, single-blind, split-face study [66]. Tanaka et al. 
[67] also compared the use of topical 5% imiquimod, with ALA-PDT but also with combina-
tion therapy in a randomized study. Although the combination group showed outstanding 
effectiveness, it was more frequently associated with adverse events, when compared to the 
PDT and imiquimod alone groups. There were no differences in either efficacy or adverse 
events between PDT and imiquimod monotherapy, however development of pigmentation 
was higher in the imiquimod therapy group.
Interestingly, imiquimod 5%, showed superiority in histological and clinical outcomes over 
MAL-PDT for face and scalp AKs, in a further randomized study [68]. The same study found 
that sequential MAL-PDT and imiquimod 5% are significantly more effective than each ther-
apy alone, indicating that combination treatment may be beneficial [68].
Compared to CO
2
 laser ablation for the treatment of multiple scalp AKs in a randomized, 
half-side comparative study ALA-PDT showed superior efficacy [69]. By hyperkeratotic AKs, 
physical or chemical keratolytic pretreatment significantly improves the uptake of photosen-
sitizer and light penetrance [70]. Topical application of 10% salicylic acid and 40% urea have 
similar efficacy to curettage, although chemical pre-treatment was associated with increased 
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pain [70]. The recent introduction of ALA patch PDT reduces the need of keratolytic treatment 
prior to PDT [71].
Efficacy of PDT for AK on acral sites is reduced by approximately 10%, probably due to a 
higher proportion of thicker lesions. Compared to cryotherapy, MAL-PDT proved to be less 
effective for acral AK (lesion clearance 78% versus 88% after 6 months) [51].
Several novel methods of delivering PDT have been used for the treatment of AK, including 
the adhesive patch, daylight, ambulatory light sources and fractionated light protocols. PDT 
using the BF-200 ALA, has been recently licensed and proven to be superior to MAL with 
clearance of 90% versus 83% of thin or moderate thickness face/scalp AK (complete clearance 
rates of 78% versus 64%) 12 weeks after one or two PDT treatments [72].
PDT is identified as an effective therapeutic option both for lesion and field treatment for AK 
and by presence of multiple and/or confluent AK, at sites of poor healing, or where there has 
been a poor response to other topical therapies [73]. Also patient tolerance to MAL-PDT or top-
ical imiquimod for multiple face/scalp AK and level of satisfaction were significantly higher 
by patients who underwent PDT treatment in a randomized comparison trial [74]. Figures 3 
and 4 present clinical outcomes of ALA-PDT in AK lesions at the head and ear of two patients.
3.2. Basal cell carcinoma
PDT is an established treatment for superficial and nodular types of BCC, but is not indi-
cated for the more aggressive or infiltrating types [75]. Response rates of PDT in the existing 
Figure 3. (A) Clinical manifestation of AKs on the head, (B) clinical outcome 4 weeks after one therapy-cycle consisting 
of double PDT-treatment in 1 week apart.
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literature vary between 70 and 90%, which may depend on the kind of tumors and the exact 
performance of PDT [76, 77]. MAL-PDT is approved in the EU for treatment of BCC, but 
remains off-label in the United States. Several studies have so far assessed the efficacy, cos-
metic results and recurrence rates of BCC treated with PDT [78–80].
PDT has proven to generally be more effective for superficial BCC as compared to nodular 
BCC and also for lesions smaller than 2 cm [65, 66, 68]. Regarding the use of PDT for the 
treatment of larger and nodular BCC, MAL-PDT has proven to be a more effective treatment 
option with lower recurrence rates as compared to ALA-PDT [66, 68].
PDT appears to have good efficacy and cosmetic outcome but results in higher BCC recur-
rence rates in comparison to surgical excision [77, 79, 81–83]. Szeimies et al. [77] reported a 
similar efficacy at 3 months for MAL-PDT and surgical excision in the management of superfi-
cial BCC in a large randomized multicenter open study (92.2% clinical lesion response versus 
99.2% in the surgical group). In a recent meta-analysis Zou et al. [83] found also that PDT is 
comparably effective to surgical excision for treatment of BCC, but with an increased risk of 
recurrence. Rhodes et al. [82] showed that the recurrence rate for primary nodular BCC after 
treatment with PDT was 14% versus 4% with surgical excision at the 5-year follow-up point. 
Data from other studies support that PDT leads to better cosmetic results compared to surgi-
cal excision [81, 82]. Also PDT serves as an effective alternative treatment option in difficult 
cases where an extensive surgical excision should have been performed carrying the risk of a 
worse cosmetic outcome [84].
When compared with cryotherapy for the treatment of superficial BCC, MAL-PDT led to 
comparable recurrence rates after 5 years, but better cosmetic results [85]. In a recent three-
year follow up randomized controlled trial Roozeboom et al. [86] compared the efficacy of 
Figure 4. (A) Clinical manifestation of AKs on the helix of the left ear, (B) clinical outcome 3 years after therapy (there has 
been performed two therapy-cycles each consisting of double PDT-treatment in 1 week apart).
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MAL-PDT, topical imiquimod and 5-FU on the treatment of superficial BCC. Topical imiqui-
mod has shown superiority to MAL-PDT (tumor-free survival 58.0% for MAL-PDT versus 
79.7% for imiquimod) but comparable results with 5-FU (68.2%).
For nodular BCC, variable response rates have been reported in several studies. Rhodes et al. 
[82] observed comparable response rates for primary nodular BCC treated with MAL-PDT or 
surgical excision at 3 months (91 and 98%, respectively), again with greater recurrence rates 
but better cosmetic outcomes in the PDT group. The same group showed in a later random-
ized study persistent complete lesion response rates at 5 years which were 76% for MAL-PDT 
und 96% for surgical excision of nodular BCC. PDT led consistently to better cosmetic out-
comes [87]. On the contrary, Mosterd et al. [88] showed in a further randomized controlled 
study of 173 primary nodular BCCs that surgical excision was significantly more effective 
compared to a single treatment of fractionated ALA-PDT, with a failure rate of 2.3% com-
pared to 30.3% for PDT at 3 year follow up. Performance of two ALA-PDT treatments for both 
nodular and superficial BCC has given comparable clinical response rates to surgery (95.83% 
complete response versus 95.65%). Recurrence rates were also similar (4.16% versus 4.34%) 
[81]. In the longest follow-up study to date lasting 10 years, Christensen et al. [89] found that 
the overall complete response rate for all subtypes of BCC treated with ALA-PDT was 75%, 
with a 60% complete response after one treatment and 87% response after two treatments.
More aggressive types of BCC, which often occur on the face, show a greater frequency 
of recurrence, possibly due to genetic mutations resulting to resistance to apoptosis [75]. 
Although long-term recurrence may limit the use of PDT for nodular BCC, PDT seems to be 
suitable for cases where surgical excision is not appropriate. On the other side, randomized 
studies with only short-term follow-up had previously reported high efficacy for facial nodu-
lar BCCs treated with MAL-PDT [90].
Since thickness of the tumor can affect the penetration capacity of the photosensitizer, vari-
ous methods have been already used prior to PDT as pre-treatment in order to enhance its 
efficacy. Therefore, dimethylsulphoxide (DMSO), which alters the intercellular lipid structure 
of the stratum corneum, has been used as a pretreatment penetration enhancer [91]. Curettage 
and DMSO pretreatment prior to one or two sessions ALA-PDT brought favorable 10-year 
response rates of 75% for primary small BCC [89]. Also intralesional ALA and light source 
application showed promising results in a small prospective study of 20 patients with nodular 
BCC, with no clinical recurrence observed after 19.5 months [92].
Combination of PDT with Mohs micrographic surgery has also been performed with benefi-
cial outcomes by reducing the tumor size and thus improving the cosmetic outcomes [93, 94].
PDT can be a useful option for patients with naevoid BCC syndrome (Gorlin syndrome) depend-
ing on the localization and thickness of the lesions [95]. In these patients can MAL-PDT signifi-
cantly improve patient satisfaction and reduce the need for many surgical procedures [96].
Although topical PDT does not serve as first-line therapy for BCC, it is recommended for 
primary superficial and thin low-risk nodular BCC but is a relatively poor choice for high-risk 
lesions including nodular BCC [97]. PDT is best considered for nodular lesions where surgi-
cal excision is relatively contraindicated, or where patient preference, reflecting past therapy 
history, comorbidities or cosmetic considerations, although the higher risk of recurrence has 
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to be taken into consideration. It is advised that patients receiving topical PDT for nodular 
BCC are reviewed for evidence of recurrence for at least 1 year. Further long-term studies are 
needed to better assess the effectiveness of PDT on BCC. Figure 5 demonstrates the treatment 
and clinical outcome after ALA-PDT on a superficial BCC.
3.3. Squamous cell carcinoma
PDT has been also used for treatment of Bowen’s disease, or squamous cell carcinoma in 
situ and is recommended for both extensive involvement and poor healing sites [98]. The 
approved MAL-PDT dosing regimen for Europe consists of two treatments 7 days apart, 
repeated at 3 months, if needed [99].
The clearance rates reported for BD lesions are high between 86 and 93% 3 months after one 
or two treatments of MAL-PDT using red light, with sustained clearance at 24 months of 
68–71%, which is comparable with the conventional therapy, but with better cosmetic out-
comes [100]. MAL-PDT was effective in treating lesions over 3 cm, with clearance rates of 
96% in 3 months after one cycle of two treatments, with only three recurrences in a follow-up 
of 1 year [101]. Comparable outcomes have been reported form an observational study of 51 
BD lesions which had been treated with two MAL-PDT treatments one week apart leading 
to clearance rates of 76.09% at 16.61 months with excellent cosmetic outcome and only mild 
cutaneous adverse effects [102].
Compared to cryotherapy and topical 5-FU, MAL-PDT showed similar response rates for 
BD at the 12 month follow-up point but superior cosmetic results [103]. Also ALA-PDT 
has been found to be significantly more effective for BD than topical 5-FU at 12 months 
(82% versus 48% complete clearance) at 12 months [104]. ALA-PDT compared to MAL-PDT, 
respectively, showed an 89% versus 78% response rate, at approximately 6 months after 
treatment [101].
Therapy guidelines recommend PDT as the treatment of choice for both large and small 
plaques of BD on poor-healing sites, representing the majority of lesions and a good choice 
Figure 5. (A) Clinical manifestation of a superficial BCC, (B) selective detection of fluorescence after application of 
ALA on the lesion during PDT, (C) clinical outcome 3 years after therapy (there has been performed one therapy-cycle 
consisting of double PDT-treatment in 1 week apart).
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for large lesions in good-healing sites [105]. However, larger studies with longer follow-up 
are needed to better assess response rates.
For invasive SCC there is a reduced efficacy of PDT where 24-month clearance rates of 57 and 
26% have been reported. The degree of cellular atypia is a negative prognostic factor, sug-
gesting that poorly differentiated keratinocytes are less sensitive to PDT because of reduced 
sensitivity to phototoxicity or decreased production of PpIX.
In some cases of invasive SCC, PDT-therapy was followed by resistance resulting in more 
aggressive disease. Gilaberte et al. [106] postulated that chromosomal instability is the reason-
able factor through the induction of overexpression of CCND1 and aberration of the MAPK/
ERK signal pathway, as previously shown in immunodeficient mice.
In view of its metastatic potential and reduced efficacy rates, PDT currently cannot be recom-
mended for invasive SCC [100].
PDT can also be a useful treatment option by organ transplant recipients who are at an 
increased risk of NMSC and especially SCC due to long-term immunosuppressive therapy. 
Treatment with cyclic ALA-PDT at 4–8 week intervals over a 2-year period on 12 organ trans-
plant recipients led to a significant reduction of SCC (98% mean reduction) [107]. Wennberg 
et al. [108] also found that repeat MAL-PDT treatments reduced the occurrence of new AKs 
in this special population.
4. Conclusions and future expectations
Since the incidence of NMSC is increasing over the years, available therapies should 
aim to deliver good cosmetic outcomes and optimize patient comfort while still achiev-
ing acceptable response rates. PDT offers an attractive alternate to surgical treatment of 
NMSC, as well as an alternate to non-surgical treatments such as cryotherapy, imiquimod 
and 5-fluorouracil. Conventional PDT is in comparison to daylight PDT a well-tolerated 
treatment method, with pain during and shortly after treatment being the main adverse 
effect.
MAL appears be associated with lower pain levels than ALA, which may be due to its 
greater selectivity for neoplastic lesions. New strategies, such as cooling and inhalation 
of a nitrous oxygen/oxygen mixture, are promising treatments to minimize pain. MAL 
also requires shorter incubation times compared to ALA, according to the FDA-approved 
treatment regimen. PDT utilizing ALA and MAL is a proven and even first line treatment 
for AK and superficial BCC. PDT has also demonstrated efficacy in treatment of nodular 
BCC and SCC in situ, although recurrence rates higher than those of standard surgical 
treatments preclude first-line use of PDT for these indications. Studies with MAL-PDT 
for superficial BCC offer acceptable response rates to consider it a reasonable therapeu-
tic option for patients who are not eligible for surgery or do not desire surgery. PDT 
should be utilized with caution for nodular BCC and Bowen’s disease given the risk of 
recurrence.
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New strategies for improving the efficacy and tolerability of PDT are under continuous devel-
opment. Although several classes of novel photosensitizers have been proposed, they seem to 
be of no advantage regarding the overall efficacy of PDT [109]. Novel delivery systems such 
as nanoparticles, micelles or liposomes which are promising technologies leading to a better 
uptake and targeting of photosensitizers may be available in the future.
New indications for PDT including cutaneous infections, inflammatory dermatoses, cutane-
ous T-cell lymphoma or treatment of skin photo aging are also under investigation.
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